Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 4NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Genitourinary 2Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × perifosine × Genitourinary × Clear all
NCT00058214 2015-02-23

Perifosine in Treating Patients With Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

NCT00060437 2013-06-19

Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡